Compare Stocks: NVS, JNJ, MRK, and AZN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$161.74 -1.5%	$163.66	$153.41 ▼ $212.71	$254.67B	0.25	2.89 million shs	2.23 million shs
JNJ Johnson & Johnson	$265.44 -0.8%	$266.53	$182.94 ▼ $281.07	$644.82B	0.24	6.00 million shs	6.27 million shs
MRK Merck & Co., Inc.	$145.74 -2.4%	$142.20	$82.01 ▼ $156.92	$368.30B	0.21	9.22 million shs	10.22 million shs
NVS Novartis	$142.75 -2.0%	$151.25	$121.57 ▼ $170.46	$278.04B	0.45	2.45 million shs	3.06 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	-1.06%	-2.36%	+0.91%	-10.69%	+10.83%
JNJ Johnson & Johnson	-1.65%	-0.55%	-0.24%	+5.48%	+47.37%
MRK Merck & Co., Inc.	+0.38%	-1.13%	+0.68%	+19.16%	+90.29%
NVS Novartis	-0.95%	+3.09%	-5.33%	-5.52%	+17.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$161.74 -1.5%	$163.66	$153.41 ▼ $212.71	$254.67B	0.25	2.89 million shs	2.23 million shs
JNJ Johnson & Johnson	$265.44 -0.8%	$266.53	$182.94 ▼ $281.07	$644.82B	0.24	6.00 million shs	6.27 million shs
MRK Merck & Co., Inc.	$145.74 -2.4%	$142.20	$82.01 ▼ $156.92	$368.30B	0.21	9.22 million shs	10.22 million shs
NVS Novartis	$142.75 -2.0%	$151.25	$121.57 ▼ $170.46	$278.04B	0.45	2.45 million shs	3.06 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	-1.06%	-2.36%	+0.91%	-10.69%	+10.83%
JNJ Johnson & Johnson	-1.65%	-0.55%	-0.24%	+5.48%	+47.37%
MRK Merck & Co., Inc.	+0.38%	-1.13%	+0.68%	+19.16%	+90.29%
NVS Novartis	-0.95%	+3.09%	-5.33%	-5.52%	+17.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN Astrazeneca	2.72	Moderate Buy	$206.67	27.78% Upside
JNJ Johnson & Johnson	2.80	Moderate Buy	$275.87	3.93% Upside
MRK Merck & Co., Inc.	2.59	Moderate Buy	$145.76	0.02% Upside
NVS Novartis	2.20	Hold	$148.40	3.96% Upside

Current Analyst Ratings Breakdown

Latest NVS, JNJ, MRK, and AZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/29/2026	JNJ Johnson & Johnson	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$278.00
9/29/2026	JNJ Johnson & Johnson	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$270.00 ➝ $285.00
9/29/2026	MRK Merck & Co., Inc.	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Outperform	$155.00 ➝ $180.00
9/23/2026	MRK Merck & Co., Inc.	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$137.00 ➝ $155.00
9/22/2026	JNJ Johnson & Johnson	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/21/2026	NVS Novartis	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell
9/17/2026	NVS Novartis	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/17/2026	NVS Novartis	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/15/2026	AZN Astrazeneca	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell ➝ Hold
9/14/2026	AZN Astrazeneca	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
9/11/2026	MRK Merck & Co., Inc.	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$127.00 ➝ $137.00

(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN Astrazeneca	$61.37B	4.09	$12.59 per share	12.85	$31.41 per share	5.15
JNJ Johnson & Johnson	$94.19B	6.79	$13.78 per share	19.26	$33.85 per share	7.84
MRK Merck & Co., Inc.	$66.57B	5.40	$11.19 per share	13.02	$21.22 per share	6.87
NVS Novartis	$56.69B	4.80	$10.44 per share	13.68	$22.04 per share	6.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN Astrazeneca	$10.23B	$6.69	24.18	15.33	1.40	17.02%	31.45%	13.20%	10/30/2026 (Estimated)
JNJ Johnson & Johnson	$26.80B	$8.63	30.76	20.69	2.60	21.48%	32.42%	13.35%	10/13/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$1.25	116.59	15.17	6.48	4.77%	16.73%	6.13%	10/29/2026 (Estimated)
NVS Novartis	$13.98B	$6.63	21.53	14.54	2.84	23.29%	38.56%	14.47%	10/27/2026 (Estimated)

Latest NVS, JNJ, MRK, and AZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/27/2026	Q3 2026	NVS Novartis	$2.24	N/A	N/A	N/A	$14.62 billion	N/A
10/13/2026	Q3 2026	JNJ Johnson & Johnson	$2.85	N/A	N/A	N/A	$25.35 billion	N/A
8/4/2026	Q2 2026	MRK Merck & Co., Inc.	-$0.26	-$0.13	+$0.13	-$0.54	$16.37 billion	$16.61 billion
7/27/2026	Q2 2026	AZN Astrazeneca	$2.50	$2.63	+$0.13	$1.61	$15.44 billion	$15.38 billion
7/21/2026	Q2 2026	NVS Novartis	$2.17	$2.41	+$0.24	$1.71	$14.07 billion	$14.41 billion
7/15/2026	Q2 2026	JNJ Johnson & Johnson	$2.84	$2.90	+$0.06	$2.27	$25.06 billion	$25.31 billion
6/30/2026	Q2 2026	NVS Novartis	N/A	$2.41	N/A	$1.71	N/A	$14.95 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN Astrazeneca	$4.34	2.68%	+2.30%	64.87%	N/A
JNJ Johnson & Johnson	$5.36	2.02%	+5.25%	62.11%	64 Years
MRK Merck & Co., Inc.	$3.40	2.33%	+5.75%	272.00%	14 Years
NVS Novartis	$3.08	2.16%	+5.28%	46.46%	N/A

Latest NVS, JNJ, MRK, and AZN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.36%	9/15/2026	9/15/2026	10/7/2026
7/15/2026	JNJ Johnson & Johnson	quarterly	$1.34	1.96%	8/25/2026	8/25/2026	9/8/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN Astrazeneca	0.47	0.89	0.67
JNJ Johnson & Johnson	0.44	1.09	0.81
MRK Merck & Co., Inc.	1.22	1.32	1.10
NVS Novartis	0.89	0.86	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN Astrazeneca	20.35%
JNJ Johnson & Johnson	69.55%
MRK Merck & Co., Inc.	76.07%
NVS Novartis	13.12%

Insider Ownership

Company	Insider Ownership
AZN Astrazeneca	N/A
JNJ Johnson & Johnson	0.16%
MRK Merck & Co., Inc.	0.17%
NVS Novartis	0.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
JNJ Johnson & Johnson	138,200	2.41 billion	2.41 billion	Optionable
MRK Merck & Co., Inc.	75,000	2.47 billion	2.46 billion	Optionable
NVS Novartis	75,267	1.91 billion	1.91 billion	Optionable

NVS, JNJ, MRK, and AZN Headlines

Recent News About These Companies

Novartis Falls as Investors Continue to Digest September Trial Setbacks

September 30 at 5:30 PM | quiverquant.comQ

Novartis AG (NVS) Shares Fall 0.8% -- What GF Score of 78 Tells Investors

September 29 at 10:00 PM | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

September 29 at 5:39 PM | globenewswire.com

Zacks Research Weighs in on Novartis' Q1 Earnings (NYSE:NVS)

September 29 at 6:58 AM | americanbankingnews.com

Zacks Research Issues Negative Outlook for Novartis Earnings

September 29 at 6:56 AM | marketbeat.com

Novartis (NYSE:NVS) Stock Sold by Rep. Kevin Hern

September 29 at 5:00 AM | marketbeat.com

Novartis (NVS) Has More Growth Ahead. Can its Portfolio Outrun Generic Pressure?

September 28 at 10:45 PM | finance.yahoo.com

Zacks Research Brokers Boost Earnings Estimates for Novartis

September 28 at 1:28 AM | americanbankingnews.com

Novartis Stock Earnings Estimates Raised by Zacks Research

September 28 at 1:26 AM | marketbeat.com

Novartis AG $NVS Shares Sold by State Street Corp

September 26, 2026 | marketbeat.com

A Top Novartis (NVS) Shareholder Says ‘The Party is Over’ for its Dealmaking Team

September 26, 2026 | finance.yahoo.com

Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover?

September 25, 2026 | insidermonkey.com

FY2027 EPS Estimates for Novartis Lifted by Erste Group Bank

September 25, 2026 | americanbankingnews.com

Envestnet Asset Management Inc. Acquires 19,595 Shares of Novartis AG $NVS

September 24, 2026 | marketbeat.com

QRG Capital Management Inc. Raises Stock Position in Novartis AG $NVS

September 23, 2026 | marketbeat.com

Novartis stock gains 0.62 percent at the close

September 23, 2026 | ad-hoc-news.deA

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

September 23, 2026 | zacks.com

FY2027 EPS Estimates for Novartis Raised by Erste Group Bank

September 23, 2026 | marketbeat.com

Novartis stock ends the day at USD 141.43 after the close

September 23, 2026 | ad-hoc-news.deA

BoomRay Pharma, Novartis Ink Radioligand Therapy Licensing Deal Worth Up To $900 Mln

September 22, 2026 | rttnews.com

Erste Group Bank Forecasts Increased Earnings for Novartis

September 22, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NVS, JNJ, MRK, and AZN Company Descriptions

Astrazeneca NYSE:AZN

$161.74 -2.47 (-1.50%)

Closing price 03:59 PM Eastern

Extended Trading

$162.00 +0.26 (+0.16%)

As of 07:45 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Johnson & Johnson NYSE:JNJ

$265.44 -2.13 (-0.80%)

Closing price 03:59 PM Eastern

Extended Trading

$265.02 -0.41 (-0.16%)

As of 07:59 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Merck & Co., Inc. NYSE:MRK

$145.74 -3.54 (-2.37%)

Closing price 03:59 PM Eastern

Extended Trading

$145.40 -0.34 (-0.23%)

As of 07:57 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Novartis NYSE:NVS

$142.75 -2.96 (-2.03%)

Closing price 03:59 PM Eastern

Extended Trading

$143.09 +0.34 (+0.24%)

As of 07:55 PM Eastern

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVS, JNJ, MRK, and AZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVS, JNJ, MRK, and AZN Earnings

Compare Dividends

Latest NVS, JNJ, MRK, and AZN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVS, JNJ, MRK, and AZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVS, JNJ, MRK, and AZN Company Descriptions

Astrazeneca NYSE:AZN

Johnson & Johnson NYSE:JNJ

Merck & Co., Inc. NYSE:MRK

Novartis NYSE:NVS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools